freeze–thaw cycle is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-01. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Most of the clitoris is composed of internal parts. Regarding humans, it consists of the glans, the body (which is composed of two erectile structures known as the corpora cavernosa), the prepuce, and the root. The frenulum is beneath the glans. Research indicates that clitoral tissue extends into the vaginal anterior wall. Şenaylı et al. said that the histological evaluation of the clitoris, "especially of the corpora cavernosa, is incomplete because for many years the clitoris was considered a rudimentary and nonfunctional organ". They added that Baskin and colleagues examined the clitoris' masculinization after dissection and using imaging software after Masson's trichrome staining, put the serial dissected specimens together; this revealed that nerves surround the whole clitoral body. The clitoris, its bulbs, labia minora, and urethra involve two histologically distinct types of vascular tissue (tissue related to blood vessels), the first of which is trabeculated, erectile tissue innervated by the cavernous nerves. The trabeculated tissue has a spongy appearance; along with blood, it fills the large, dilated vascular spaces of the clitoris and the bulbs. Beneath the epithelium of the vascular areas is smooth muscle. As indicated by Yang et al.'s research, it may also be that the urethral lumen (the inner open space or cavity of the urethra), which is surrounded by a spongy tissue, has tissue that "is grossly distinct from the vascular tissue of the clitoris and bulbs, and on macroscopic observation, is paler than the dark tissue" of the clitoris and bulbs.
However, the failure of D2 dopamine receptor antagonism, or dopamine receptor dysfunction, do not fully explain the presenting symptoms and signs of NMS, as well as the occurrence of NMS with atypical antipsychotic drugs with lower D2 dopamine activity. This has led to the hypothesis of sympathoadrenal hyperactivity (results from removing tonic inhibition from the sympathetic nervous system) as a mechanism for NMS. Release of calcium is increased from the sarcoplasmic reticulum with antipsychotic usage. This can result in increased muscle contractility, which can play a role in the breakdown of muscle, muscle rigidity, and hyperthermia. Some antipsychotic drugs, such as typical antipsychotics, are known to block dopamine receptors; other studies have shown that when drugs supplying dopamine are withdrawn, symptoms similar to NMS present themselves. In support of the sympathoadrenal hyperactivity model, it has been hypothesized that a defect in calcium regulatory proteins within the sympathetic neurons may bring about the onset of NMS. This model of NMS strengthens its suspected association with malignant hyperthermia in which NMS may be regarded as a neurogenic form of this condition which itself is linked to defective calcium-related proteins. There is also thought to be considerable overlap between malignant catatonia and NMS in their pathophysiology, the former being idiopathic and the latter being the drug-induced form of the same syndrome.
The growth of bacteria in laboratory cultures is the mainstay method used by bacteriologists. Both solid and liquid culture media are used. Solid culture medium is usually nutrient agar in a petri dish. The constituents of the nutrient agar vary according to the bacteria under investigation. For growing the bacterium Haemophilus influenzae, for example, which is dependent on hemin and nicotinamide adenine dinucleotide for its growth, blood (usually from a sheep or a horse) is added to the medium. When growing bacteria that are found in the intestines of mammals, such as salmonella, XLD agar which contains, among other ingredients deoxycholic acid is used.
25% of patients treated with arsenic trioxide exhibited symptoms resembling leukocyte activation syndrome, characterized by high fever, shortness of breath, weight gain, pulmonary infiltrates with pleural or pericardial exudation, with or without leukocytosis. High doses of steroids (10 mg dexamethasone intravenously, 2–3 times per day) appear to alleviate these symptoms. 40% of patients treated with arsenic trioxide experienced at least one instance of prolonged QT interval, corrected to over 500 ms. QT interval prolongation can lead to ventricular arrhythmias, such as torsades de pointes. Prior to initiating arsenic trioxide treatment, an ECG should be performed, and blood levels of potassium, calcium, magnesium, and creatinine should be checked. Any abnormalities, particularly a prolonged QT interval on the ECG, should be corrected before starting arsenic trioxide. Any medications that may prolong the QT interval should be discontinued if possible. Patients receiving arsenic trioxide, particularly those at risk for torsades de pointes, should be closely monitored during treatment. If toxicity reaches level 3 (as per National Cancer Institute criteria), treatment should be modified or discontinued before the planned completion of therapy. Patients can resume treatment only after symptoms subside, starting with 50% of the prior daily dose. The dose can be increased to the previous level if no toxicity symptoms appear within 3 days. If toxicity reappears, treatment with arsenic trioxide cannot continue.
It also plays an important role in fine motor control; Parkinson's disease has been linked to low levels of dopamine due to the loss of dopaminergic neurons in substantia nigra pars compacta. Schizophrenia, a highly heterogeneous and complicated disorder has been linked to high levels of dopamine. Serotonin is a monoamine neurotransmitter. Most of it is produced by the intestine (approximately 90%), and the remainder by central nervous system neurons at the raphe nuclei. It functions to regulate appetite, sleep, memory and learning, temperature, mood, behaviour, muscle contraction, and the functions of the cardiovascular system and endocrine system. It is speculated to have a role in depression, as some depressed patients have been reported to exhibit lower concentrations of metabolites of serotonin in their cerebrospinal fluid and brain tissue. Norepinephrine is a member of the catecholamine family of neurotransmitters. It is synthesized from the amino acid tyrosine. In the peripheral nervous system, one of the primary roles of norepinephrine is to stimulate the release of the stress hormone epinephrine (i.e. adrenaline) from the adrenal glands. Norepinephrine is involved in the fight-or-flight response and is also affected in anxiety disorders and depression. Epinephrine, a neurotransmitter and hormone is synthesized from tyrosine. It is released from the adrenal glands and also plays a role in the fight-or-flight response. Epinephrine has vasoconstrictive effects, which promote increased heart rate, blood pressure, energy mobilization.
Sources: en.wikipedia.org
West of Borgo Dora stands Rione Valdocco ('Valdocco neighbourhood'), enclosed by Via Cigna, Corso Regina Margherita, Corso Principe Oddone and the River Dora. This neighbourhood hosts the significant architecture of Santuario di Maria Ausiliatrice ('Maria Ausiliatrice Sanctuary') in the homonymous square and behind the church stands San Pietro in Vincoli old cemetery. Overall, the main thoroughfares of the West side of Aurora are Via Cigna, which crosses the district from north to south, Corso Vercelli, a historical avenue starting north of the River Dora, and Corso Principe Oddone, part of the long Spina Centrale boulevard that will be built over the underground Turin-Milan railway. However, the Spina Centrale project is proceeding slowly because of the lack of funds and the boulevard is still occupied by a large worksite along its span. Once completed, Aurora district will be connected to Eastern San Donato, thanks to a better connection among the roads of the two adjacent districts (i.e. Corso Ciriè will continue in Corso Gamba and Strada del Fortino in Corso Rosai). As for the rest of Aurora, the district is crossed by an important thoroughfare named Corso Giulio Cesare, a long boulevard that extends from Porta Palazzo up to Turin-Trieste motorway entrance in the northern urban fringe of Turin. Other significant roads are Corso Palermo, Via Bologna and Corso Regio Parco, mostly in the East side of Aurora which is known as Borgo Rossini ('Rossini Borough').
=== 18 December === The Russian government recruited musicians to boost morale. The so-called "front-line creative brigade" was to be made up from mobilised soldiers and musicians who have volunteered.
=== Wound healing === Historically, hydrogen peroxide was used for disinfecting wounds, partly because of its low cost and prompt availability compared to other antiseptics. There is conflicting evidence on hydrogen peroxide's effect on wound healing. Some research finds benefit, while other research find delays and healing inhibition. Its use for home treatment of wounds is generally not recommended. 1.5–3% hydrogen peroxide is used as a disinfectant in dentistry, especially in endodontic treatments together with hypochlorite and chlorhexidine and 1–1.5% is also useful for treatment of inflammation of third molars (wisdom teeth).
=== Measuring instruments === Many devices are used to measure the pressure in a vacuum, depending on what range of vacuum is needed. Hydrostatic gauges (such as the mercury column manometer) consist of a vertical column of liquid in a tube whose ends are exposed to different pressures. The column will rise or fall until its weight is in equilibrium with the pressure differential between the two ends of the tube. The simplest design is a closed-end U-shaped tube, one side of which is connected to the region of interest. Any fluid can be used, but mercury is preferred for its high density and low vapour pressure. Simple hydrostatic gauges can measure pressures ranging from 1 torr (100 Pa) to above atmospheric. An important variation is the McLeod gauge which isolates a known volume of vacuum and compresses it to multiply the height variation of the liquid column. The McLeod gauge can measure vacuums as high as 10−6 torr (0.1 mPa), which is the lowest direct measurement of pressure that is possible with current technology. Other vacuum gauges can measure lower pressures, but only indirectly by measurement of other pressure-controlled properties. These indirect measurements must be calibrated via a direct measurement, most commonly a McLeod gauge. The kenotometer is a particular type of hydrostatic gauge, typically used in power plants using steam turbines. The kenotometer measures the vacuum in the steam space of the condenser, that is, the exhaust of the last stage of the turbine.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.